Skip to main content

GENELUX Corp

GNLX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001231457

In the last 90 days, GENELUX Corp insiders filed 0 open-market purchases and 7 sales; 72 institutions reported holding it in 13F filings for Q2 2026, worth $29.5M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by GENELUX Corp insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
7 filings
4 insiders, $194.3K in total
Insiders trading
4
Net value
−$194.3K
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for GENELUX Corp, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for GENELUX Corp
NameTitleLast reported holdingLast filingFilings, past year
Cappello JosephChief Technical Officer318,480Sep 2, 20266
Zindrick ThomasPresident and CEO1,226,427Sep 2, 20266
Yu TonyChief Scientific Officer258,688Sep 2, 20266
Smither John WDirector91,403Jul 2, 20262
Tyree James LDirector96,483Jun 18, 20261
Groen EricGeneral Counsel233,957Jun 18, 20261
Mirabelli MaryDirector102,693Jun 18, 20261
Thomas JohnDirector501,193Jun 18, 20264
Pulisic MatthewChief Financial Officer278,906Jun 18, 20261
Smalling RalphHead of Regulatory67,611Jun 4, 20264
Litten JasonChief Medical Officer–Jan 7, 20261
Ryder SeanGeneral Counsel47,621May 13, 20250
Zak Lourie S.Chief Financial Officer82,452Dec 20, 20240
Scigalla PaulChief Medical Officer–Oct 21, 20240
Szalay Aladar10% Owner599,821IndirectSep 13, 20240
Jewett CarolineHead of Quality16,174Jul 8, 20240
Samuelson DougVice President, Finance2,303Sep 12, 20230
Zhang QianAssociate VP, Research139,333May 2, 20230
Woodward GabeDirector4,186May 2, 20230

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 2, 2026 (view filing)7:05 PM ETAug 312 daysCappello JosephChief Technical OfficerSSale−10.3K$2.74−$28.1K−3.1%318.5K after
Sep 2, 2026 (view filing)7:05 PM ETAug 312 daysZindrick ThomasPresident and CEOSSale−34.5K$2.67−$91.9K−2.7%1.23M after
Sep 2, 2026 (view filing)7:05 PM ETAug 312 daysYu TonyChief Scientific OfficerSSale−9.68K$2.75−$26.7K−3.6%258.7K after
Aug 4, 2026 (view filing)8:20 PM ETAug 4Same dayYu TonyChief Scientific OfficerSSale−653$2.94−$1.92K−0.2%268.4K after
Aug 4, 2026 (view filing)8:20 PM ETAug 4Same dayCappello JosephChief Technical OfficerSSale−653$2.95−$1.92K−0.2%328.7K after
Aug 4, 2026 (view filing)8:20 PM ETAug 4Same dayZindrick ThomasPresident and CEOSSale−3.02K$2.95−$8.91K−0.2%1.26M after
Jul 2, 2026 (view filing)4:35 PM ETJul 11 daySmither John WDirectorSSale−12.0K$2.91−$34.9K−11.6%91.4K after
Jun 4, 2026 (view filing)Jun 31 daySmalling RalphHead of RegulatorySSale−192$2.93−$562.56−0.3%67.6K after
Jun 2, 2026 (view filing)Jun 11 dayThomas JohnDirectorSSale−10.0K$2.98−$29.8K−2.1%472.8K after10b5-1
May 12, 2026 (view filing)May 111 dayCappello JosephChief Technical OfficerSSale−605$2.97−$1.80K−0.4%154.5K after
May 12, 2026 (view filing)May 111 dayYu TonyChief Scientific OfficerSSale−605$2.97−$1.80K−0.4%149.7K after
May 12, 2026 (view filing)May 111 dayZindrick ThomasPresident and CEOSSale−2.80K$2.94−$8.23K−0.5%532.1K after
May 12, 2026 (view filing)May 111 daySmalling RalphHead of RegulatorySSale−270$2.98−$804.6−0.4%67.8K after
Mar 26, 2026 (view filing)Mar 24-252 daysSmalling RalphHead of RegulatorySSale−585$2.46−$1.44K−0.9%68.1K after2 lots
Mar 26, 2026 (view filing)Mar 242 daysCappello JosephChief Technical OfficerSSale−906$2.42−$2.19K−0.6%155.2K after
Mar 26, 2026 (view filing)Mar 242 daysYu TonySVP, Clinical DevelopmentSSale−906$2.42−$2.19K−0.6%144.9K after
Mar 26, 2026 (view filing)Mar 242 daysZindrick ThomasPresident and CEOSSale−3.58K$2.42−$8.67K−0.7%534.8K after
Mar 3, 2026 (view filing)Mar 21 dayThomas JohnDirectorSSale−10.0K$2.90−$29.0K−2.0%482.8K after10b5-1
Dec 11, 2025 (view filing)Aug 21-Nov 17112 daysLateZindrick ThomasPresident and CEOSSale−17.2K$3.87−$66.4K−3.1%538.4K after2 lots
Dec 11, 2025 (view filing)Aug 21-Nov 17112 daysLateYu TonySVP, Clinical DevelopmentSSale−4.19K$3.83−$16.0K−2.8%145.8K after2 lots
Dec 11, 2025 (view filing)Aug 21-Nov 17112 daysLateCappello JosephChief Technical OfficerSSale−3.71K$3.88−$14.4K−2.3%156.1K after3 lots
Dec 9, 2025 (view filing)Aug 21-Dec 5110 daysLateSmalling RalphHead of RegulatorySSale−2.33K$3.75−$8.74K−3.3%68.7K after4 lots
Dec 2, 2025 (view filing)Dec 11 dayThomas JohnDirectorSSale−10.0K$5.00−$50.0K−2.0%492.8K after10b5-1
May 13, 2025 (view filing)May 121 dayRyder SeanGeneral CounselSSale−4.47K$2.92−$13.1K−8.6%47.6K after
May 13, 2025 (view filing)May 121 dayZindrick ThomasPresident and CEOSSale−10.8K$2.92−$31.4K−5.3%191.4K after
May 13, 2025 (view filing)May 121 dayYu TonyVP, Clinical Trial OperationsSSale−5.58K$2.92−$16.3K−10.5%47.6K after
May 13, 2025 (view filing)May 121 dayCappello JosephVP, Pharmaceutical DevelopmentSSale−4.74K$2.92−$13.8K−8.3%52.3K after
May 13, 2025 (view filing)May 121 daySmalling RalphHead of RegulatorySSale−1.26K$2.92−$3.68K−3.5%34.8K after
Dec 30, 2024 (view filing)Dec 30Same dayTyree James LDirectorSSale−3.46K$2.46−$8.51K−7.0%45.8K after
Dec 18, 2024 (view filing)Dec 162 daysZindrick ThomasPresident and CEOSSale−14.3K$2.34−$33.5K−27.7%37.4K after
Dec 18, 2024 (view filing)Dec 162 daysZak Lourie S.Chief Financial OfficerSSale−2.10K$2.34−$4.92K−4.9%40.8K after
Dec 18, 2024 (view filing)Dec 162 daysSmalling RalphHead of RegulatorySSale−2.51K$2.34−$5.87K−13.3%16.3K after
Dec 18, 2024 (view filing)Dec 162 daysCappello JosephVP, Pharmaceutical DevelopmentSSale−6.30K$2.34−$14.7K−30.1%14.7K after
Sep 13, 2024 (view filing)Sep 12-131 daySzalay Aladar10% OwnerSSale−64.9K$2.65−$171.8K−9.8%599.8K after2 lots
Sep 11, 2024 (view filing)Sep 9-112 daysSzalay Aladar10% OwnerSSale−75.1K$2.62−$196.5K−10.2%664.7K after3 lots
Sep 6, 2024 (view filing)Sep 33 daysLateSzalay Aladar10% OwnerSSale−42.8K$2.09−$89.5K−5.5%739.8K after
Aug 30, 2024 (view filing)Aug 28-302 daysSzalay Aladar10% OwnerSSale−265.6K$2.09−$554.0K−25.3%782.6K after3 lots
Aug 27, 2024 (view filing)Aug 23-274 daysSzalay Aladar10% OwnerSSale−91.6K$2.19−$200.5K−8.0%1.05M after2 lots
Jul 8, 2024 (view filing)Jun 2414 daysLateYu TonyVP, Clinical Trial OperationsSSale−6.85K$2.12−$14.5K−38.7%10.9K after
Jul 8, 2024 (view filing)Jun 2414 daysLateRyder SeanGeneral CounselSSale−5.50K$2.12−$11.7K−22.1%19.4K after
Jul 8, 2024 (view filing)Jun 2414 daysLateJewett CarolineHead of QualitySSale−4.96K$2.12−$10.5K−23.5%16.2K after
Jun 7, 2024 (view filing)May 299 daysLateTyree James LDirectorPPurchase+6.25K––+180.6%9.71K after
Jun 7, 2024 (view filing)May 299 daysLateTyree James LDirectorPPurchase+6.25K–––6.25K afterDerivative
Jun 7, 2024 (view filing)May 299 daysLateSmither John WDirectorPPurchase+6.25K––+90.3%13.2K after
Jun 7, 2024 (view filing)May 299 daysLateSmither John WDirectorPPurchase+6.25K–––6.25K afterDerivative
Jun 7, 2024 (view filing)May 299 daysLateThomas JohnDirectorPPurchase+2.50K––+0.5%466.0K after
Jun 7, 2024 (view filing)May 299 daysLateThomas JohnDirectorPPurchase+2.50K–––2.50K afterDerivative
Jun 7, 2024 (view filing)May 299 daysLateMirabelli MaryDirectorPPurchase+8.00K––+179.4%12.5K after
Jun 7, 2024 (view filing)May 299 daysLateMirabelli MaryDirectorPPurchase+8.00K–––8.00K afterDerivative
Jun 7, 2024 (view filing)May 299 daysLateYu TonyVP, Clinical Trial OperationsPPurchase+2.50K––New position2.50K after